XOMA Corporation (XOMA) : The consensus price target for XOMA Corporation (XOMA) is $1.62 for the short term with a standard deviation of $1.2. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $3, however, the pessimist price target for the company is $1.
XOMA Corporation (XOMA) : 5 analysts are covering XOMA Corporation (XOMA) and their average rating on the stock is 2.6, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
XOMA Corporation (NASDAQ:XOMA): The stock opened at $0.57 on Thursday but the bulls could not build on the opening and the stock topped out at $0.59 for the day. The stock traded down to $0.56 during the day, due to lack of any buying support eventually closed down at $0.56 with a loss of -0.79% for the day. The stock had closed at $0.57 on the previous day. The total traded volume was 246,846 shares.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).